Rhumbline Advisers Increases Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rhumbline Advisers boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 7.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 359,175 shares of the company’s stock after buying an additional 25,143 shares during the period. Rhumbline Advisers owned 0.09% of Recursion Pharmaceuticals worth $1,900,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Private Trust Co. NA acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $27,000. Farther Finance Advisors LLC lifted its stake in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after buying an additional 1,353 shares in the last quarter. NewEdge Advisors LLC lifted its stake in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock valued at $53,000 after buying an additional 2,387 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $54,000. Finally, PNC Financial Services Group Inc. raised its holdings in Recursion Pharmaceuticals by 220.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company’s stock valued at $66,000 after acquiring an additional 6,758 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RXRX has been the subject of a number of recent analyst reports. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday. Finally, Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $7.00.

Recursion Pharmaceuticals Trading Down 3.2%

NASDAQ RXRX opened at $4.84 on Wednesday. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11. The firm’s fifty day moving average is $4.91 and its two-hundred day moving average is $6.30. The firm has a market cap of $1.97 billion, a PE ratio of -2.73 and a beta of 0.84.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the firm earned ($0.39) earnings per share. The company’s revenue was up 7.2% compared to the same quarter last year. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.